PHARMACODYNAMIC ASSAYS FOR WNT/FRIZZLED AND HGF/C-MET SIGNALIN

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N43CO201000104
Agency Tracking Number: N43CO201000104
Amount: $149,678.00
Phase: Phase I
Program: SBIR
Awards Year: 2010
Solitcitation Year: 2010
Solitcitation Topic Code: NCI
Solitcitation Number: PHS2010-1
Small Business Information
MESO SCALE DIAGNOSTICS, LLC
9238 GAITHER RD, GAITHERSBURG, MD, 20877-
Duns: 113033224
Hubzone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Anu Mathew
Business Contact
Phone: (240) 631-2522
Email: cclinton@mesoscale.com
Research Institution
N/A
Abstract
Multiplexed assays for pharmacodynamic targets of high priority for the NCI will be developed using Meso Scale Diagnostics' (MSD) Multi-Array technology to facilitate multiple integrated pharmacodynamic readouts from a single tumor biopsy or surrogate tissue specimen. These assays will be suitable for measurement of molecular-level responses to treatment in conjunction with preclinical development of therapeutic agents. Assays will be developed to evaluate the Wnt/Frizzled and HGF/c-Met signaling pathways implicated in many malignancies, including renal cell carcinoma (RCC). These assays will be demonstrated in pre-clinical models, characterized cell lines, tumor xenograft tissues, and patient plasma samples. Optimized assays will be applied to patient samples in subsequent Phase 2 work, in collaboration with the NCI. Pre-clinical samples will be from commercial vendors or provided by our collaborators, Drs. Mier and Panka (Harvard University) from ongoing studies on treatment effects in cancer. MSD's multiplex capability (including measuring total and phosphorylated signaling proteins), exquisite assay sensitivity, minimal sample requirement, wide dynamic ranges, and ease of assay scalability, make this technology ideally suited to achieving the NCI's objectives for molecular pharmacodynamic applications. This research will provide valuable tools to evaluate and validate new anti-cancer agents in clinical trials and for eventual clinical use to monitor treatment.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government